BOTTINI & BOTTINI, INC. Francis A. Bottini, Jr. (SBN: 175783) Yury A. Kolesnikov (SBN: 271173) San Francisco County Superior Court 7817 Ivanhoe Avenue, Suite 102 La Jolla, California 92037 JAN 07 2020 Telephone: (858) 914-2001 Facsimile: (858) 914-2002 5 Counsel for Plaintiff Daniel Grove 6 7 8 SUPERIOR COURT OF THE STATE OF CALIFORNIA 9 FOR THE COUNTY OF SAN FRANCISCO 10 DANIEL GROVE, on behalf of himself and all Case N CGC - 20 - 582059 11 others similarly situated and derivatively on Class Action behalf of JUUL LABS, INC., 12 SHAREHOLDER CLASS ACTION AND 13 Plaintiff. DERIVATIVE COMPLAINT FOR BREACH OF FIDUCIARY DUTY. 14 VS. AIDING AND ABETTING BREACH OF ADAM BOWEN, JAMES MONSEES, 15 FIDUCIARY DUTY, VIOLATION OF NICHOLAS J. PRITZKER, K.C. CAL. CORP. CODE § 1601 ET SEQ., 16 CROSTHWAITE, GUY CARTWRIGHT, UNJUST ENRICHMENT, ABUSE OF JARED FIX, GERALD F. MASOUDI, KEVIN CONTROL, AND DECLARATORY 17 BURNS, TIMOTHY DANAHER, and DOES 1-AND INJUNCTIVE RELIEF 18 **DEMAND FOR JURY TRIAL** Defendants, 19 – and – .20 JUUL LABS, INC., a Delaware corporation, 21 Defendant and Nominal Defendant. 22 23 24 25 26 27 28

Plaintiff Daniel Grove, by his attorneys, alleges the following on information and belief, except as to the allegations specifically pertaining to Plaintiff, which are based on personal knowledge.

1

26

27

- Plaintiff brings this class action on behalf of the minority stockholders of JUUL Labs, Inc. ("JUUL" or the "Company") against JUUL and its Board of Directors (the "Board" or the "Individual Defendants") for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, violation of Cal. Corp. Code § 1601 et seq., unjust enrichment, abuse of control, and declaratory as well as injunctive relief. Defendants' actions are substantially unfair to JUUL's minority shareholders and
- JUUL designs, manufacturers, and markets electronic cigarettes and vaping products
- The Company's officers and directors have abused their control of the Company to benefit themselves personally to the detriment of the Company's minority shareholders and have
- At the same time, the Defendants have breached their fiduciary duties and violated California law by failing to provide financial information, annual reports, and other basic information to the minority shareholders, thus inhibiting their ability to discover the true worth of their stock.
- After negotiating a \$12.8 billion investment in the Company by Altria, Defendants paid themselves a special dividend/bonus, thus taking substantial liquidity out of the Company that could have been used for corporate purposes, but did not pay a dividend/bonus to all shareholders and usurped for themselves a disproportionate amount of the dividend/bonus. Additionally, the Defendants have treated the minority shareholders unfairly by imposing restrictions on their sale of Company stock restrictions which do not apply to the Defendants or which they are free to waive due to their control of
- Moreover, both before and after disbursement of the special dividend/bonus, the Defendants engaged in substantial wrongdoing, mismanagement, and breaches of fiduciary duty that resulted in an enormous decrease in the valuation of the Company, from \$38 billion a year ago to just

THE PARTIES

- 19. Plaintiff Daniel Grove is a current shareholder of JUUL Labs, Inc. and has continuously owned JUUL stock at all relevant times. Plaintiff is a resident and citizen of California.
- Defendant and Nominal Defendant JUUL Labs, Inc. is a Delaware corporation with its principal place of business at 560 20th Street, San Francisco, CA 94107. Upon information and belief, JUUL has approximately 1500 employees and revenues of approximately \$2 billion per year.
- 21. Defendant ADAM BOWEN ("Bowen") is the Chief Technology Officer, a co-founder, and a member of the Board of JUUL. Bowen has been an officer & director of the Company at all relevant times. Bowen has used his control of the Company to allow himself to sell over \$500 million of the Company's stock since the Company was founded. Defendant Bowen lives in San Mateo, California and is a resident and citizen of California.
- Defendant JAMES MONSEES ("Monsees") is the Chief Product Officer, a co-founder, and a member of the Board of Directors of JUUL. Monsees has been an officer and director of the Company at all relevant times. Monsees has used his control of the Company to allow himself to sell over \$500 million of the Company's stock since the Company was founded. Monsees is a resident and citizen of San Francisco, California.
- Defendant NICHOLAS J. PRITZKER is a Director of JUUL, and has been at all relevant times. Pritzker is a resident of San Francisco, CA.
- 24. Defendant K.C. CROSTHWAITE ("Crosthwaite") is the Chief Executive Officer of JUUL. Crosthwaite has been an officer of the Company at all relevant times.
- Defendant GUY CARTWRIGHT ("Cartwright") is the Chief Financial Officer of JUUL. Cartwright has been an officer of the Company at all relevant times.
- Defendant JARED FIX ("Fix") is the Chief Commercial Officer of JUUL, and has been since November 2019. Fix was Chief Strategy Officer of JUUL from October 2018 to November 2019, and has been an officer of the Company at all relevant times. Fix is a resident and citizen of San Francisco, California.
- 27. Defendant GERALD F. MASOUDI ("Masoudi") is the Chief Legal Officer of JUUL.

 Masoudi has been an officer of the Company at all relevant times.

intentionally concealed and attempted to disguise the unlawful conduct to avoid detection by the

48. JUUL was previously known as Pax Labs. On June 1, 2015, Pax Labs launched its JUUL vaping device at a launch party in New York City. A trove of images collected by Stanford researchers suggested that the campaign focused on a young audience. Guests were invited to try JUUL's products free and share selfies on social media, Business Insider reported. "Juul's launch campaign was patently youth-oriented," Robert Jackler, a practicing Stanford physician who was the principal investigator behind the tobacco-image collection, told a reporter with Business Insider. ¹

- 49. After the launch party in NYC, JUUL devices gained popularity. Sales rose 700% in 2016.
- 50. Juul's products have become immensely popular among teenagers, raising concerns among the public health community that long-term declines in youth nicotine use are being reversed. An October 2018 study of 13,000 Americans found that 9.5% of teenagers aged 15–17 and 11% of young adults aged 18–21 currently use JUUL, and that teenagers age 15–17 are 16 times more likely to be JUUL users than 25–34 year olds. JUUL use is also very popular among middle school and high school students; with one in five students between 12 and 17 having seen a JUUL used in school. Teenagers use the verb "Juuling" to describe their use of JUUL.
- 51. The Individual Defendants caused JUUL to enlist the services of social media "influencers"—social media personalities with large followings—to promote JUUL's products.
- 52. Stanford University's investigation culminated in a report dated Jan. 31, 2019 entitled "JUUL Advertising Over its First Three Years on the Market" which included the following conclusion: "JUUL's advertising imagery in its first 6 months on the market was patently youth oriented. For the next 2 ½ years it was more muted, but the company sadvertising was widely distributed on social media channels frequented by youth, was amplified by hashtag extensions, and catalyzed by compensated influencers and affiliates." The Stanford Report analyzed JUUL's marketing campaign between its launch in 2015 and fall 2018. The researchers scrutinized thousands of social media posts

¹ See Erin Brodwin, "The precarious path of e-cig startup Juul: From Silicon Valley darling to \$24 billion behemoth under criminal investigation," THE BUSINESS INSIDER, Oct. 31, 2019, available at https://www.businessinsider.com/juul-timeline-from-startup-to-tobacco-company-challenges-bans-2019-9.

- 57. From the beginning, the Individual Defendants were well aware that the Company's products would be subject to significant regulations and scrutiny, and eventually be subject to FDA rules and regulations. As the officers and directors of the Company, the Individual Defendants thus had a heightened fiduciary duty to ensure the Company's compliance with all applicable rules and regulations. They understood that increased governmental scrutiny or regulation of the Company's products could be very detrimental to the Company. As smokers themselves, Defendants Monsees and Bowen were well aware of the health risks of smoking and e-cigarettes.
- 58. In May 2016, the FDA issued a final rule, effective August 8, 2016, that deemed electronic nicotine delivery systems which includes e-cigarettes and the nicotine juices they use subject to the FDA's regulatory authority. Under the rule, years of regulatory and legislative requirements in place for combustible cigarettes became applicable to e-cigarettes. Those regulations included, among other things, that new tobacco products could be marketed only after FDA review.
- 59. The FDA gave JUUL and other e-cigarette manufacturers until 2022 to submit a premarket tobacco application. After public health and medical groups, including the American Academy of Pediatrics, filed suit, Judge Grimm in the United States District Court for the District of Maryland ordered the FDA to move up the deadline to May 2020.
- 60. In response to mounting criticism and pressure, in November 2018, JUUL announced that it "stopped accepting retail orders for our Mango, Fruit, Crème, and Cucumber JUUL pods to the over 90,000 retail stores that sell our product." But, until recently, JUUL continued selling those flavors on its website and continued selling the highly-popular Mint flavor in retail stores. An April 2018 survey indicated that JUUL's "cool" mint flavor was the third-most popular flavor amongst JUUL users aged 12-17.
- Defendants told the Company's employees and investors that JUUL's vaping products were safer than traditional cigarettes, and that JUUL sought to take away market share from "Big Tobacco" by developing its alternative products. The Company's employees and investors were thus shocked when Defendants orchestrated a massive investment in the Company by Altria Group, Inc. ("Altria") of \$12.8 billion in December 2018 for a 35% stake in the Company. Based on this investment, JUUL was valued at \$38 billion in December 2018.

- 62. On April 3, 2019, the FDA announced an investigation into 35 cases of people suffering seizures after "vaping." On August 29, 2019, the Wall Street Journal reported that the U.S. Federal Trade Commission was investigating whether JUUL used marketing practices to appeal e-cigarettes to minors. Several other federal and state investigations into health risks of vaping, as well as JUUL's marketing practices, are ongoing.
- 63. In June of 2019, San Francisco became the first major city to ban the sale and distribution of e-cigarettes that have not undergone pre-market review by the FDA. Juul's e-cigarettes have not undergone that review. San Francisco City Attorney Dennis Herrera said the ban is a step toward preventing "another generation of San Francisco children from becoming addicted to nicotine."
- 64. In response, the Individual Defendants caused JUUL to contribute more than \$18 million to a ballot initiative to overturn the ban. As criticism of JUUL's actions grew, JUUL abruptly ended its support of the initiative in September 2019, after the initiative had qualified for the ballot. In early November 2019, San Franciscans voted down the JUUL-sponsored initiative. The ban is scheduled to go into effect on January 1, 2020.
- Oversight and Reform held hearings at which JUUL executives and anti-tobacco witnesses testified. The hearings sought to investigate "JUUL's role in the youth nicotine addiction epidemic, marketing to youth, misleading health claims, and new partnerships with traditional tobacco companies." The hearings included appearances from students and parents who testified that JUUL representatives spoke at their schools, telling students that JUUL was "totally safe," "much safer than cigarettes," and that a student "should mention JUUL to his [nicotine-addicted] friend."
- Gretchen Whitmer ordered the ban in response to the state's health department finding youth vaping constituted a public health emergency and marketing targeting youth. Whitmer banned misleading descriptions of vaping products as "clear," "safe," and "healthy." "Companies selling vaping products are using candy flavors to hook children on nicotine and misleading claims to promote the belief that these products are safe," Ms. Whitmer said. Bills to prohibit sales of flavored vaping products have been introduced in California and Massachusetts.

- 67. On September 25, 2019, Altria announced that Philip Morris International Inc. had called off a reported \$200 billion merger with Altria, reportedly due to increasing scrutiny of vaping and Altria's 35% stake in JUUL.
- Defendants have breached their fiduciary duties of loyalty and good faith by preferring their own interests over those of the Company and taking action that has harmed the Company and its minority shareholders.
 - A. The Federal Government Alleges That Defendants Caused JUUL to Falsely Advertise that Vaping Is Safer than Smoking Traditional Cigarettes
- 69. On Monday, September 9, 2019, Federal health authorities alleged that JUUL unlawfully marketed its electronic cigarettes as a safer alternative to smoking, and ordered the Company to stop making unproven claims regarding its products.
- The FDA also increased its scrutiny of a number of key aspects of JUUL's business, forcing the Company to turn over documents on its marketing, educational programs and nicotine formula. The FDA action increased the legal pressure on JUUL, which has recently been besieged by scrutiny from state and federal officials since a recent surge in underage vaping. Federal law bans sales to those under 18. The FDA has been investigating JUUL for months but had not previously taken action against the Company.
- 71. In a sternly worded warning letter, the FDA flagged various claims made by JUUL representatives, including that its products are "much safer than cigarettes." Currently no vaping product has been federally reviewed to be less harmful than traditional tobacco-products.
- 72. During Congressional testimony, Congress heard testimony from Phillip Fuhrman. By the ninth grade, Phillip Fuhrman was already addicted to JUUL, as were many of his friends. Some of them had reservations about using the e-cigarettes. But their concerns about vaping were quickly explained away by a speaker who visited their school in April 2018 to give a presentation about mental health and addiction. Fuhrman testified to Congress in July 2019 that the speaker said he was connected to Juul, and told the kids that e-cigarettes were "totally safe" and that the FDA would soon announce that Juul products were 99 percent safer than regular cigarettes.

- 73. These marketing techniques were common and well documented, according to Robert Jackler, a researcher at Stanford who studies e-cigarette marketing. "This has been going on for years," says Jackler, who also testified at the two-day congressional hearing on e-cigarettes in July. He speculates the FDA is reacting to pressure from US Representative Raja Krishnamoorthi (D-Illinois), who chaired the hearing, and from Senator Dick Durbin (D-Illinois). Both Krishnamoorthi and Durbin have urged the FDA to take action in recent weeks to curb the youth vaping epidemic.
- On September 9, 2019, the FDA chastised JUUL for these and other scientifically unsubstantiated claims that advertise e-cigarettes as "modified risk tobacco products," suggesting they are safe, relatively risk-free ways to quit smoking. Marketers can't make those claims unless the FDA has reviewed the products and agrees that the company has rigorous scientific data to back them up. In a separate letter, the FDA requested JUUL turn over information about its youth marketing strategies and JUUL's use of nicotine salts.
- In the past year, JUUL has tried to position its e-cigarettes as a tool to help adult smokers stop smoking, using the tagline "Make the Switch." In a separate letter to the Company, the FDA said it is "concerned" that its campaign suggests "that using Juul products poses less risk or is less harmful than cigarettes".
- "JUUL has ignored the law, and very concerningly, has made some of these statements in school to our nation's youth," said FDA acting commissioner Ned Sharpless, in a statement. In a letter to JUUL CEO Kevin Burns, FDA regulators said they were "troubled" by a number of other points raised at the congressional hearing. The letter cites congressional testimony that JUUL's advertising "saturated social media channels frequented by underage teens," and "used influencers and discount coupons to attract new customers."
- 77. Last year, JUUL closed down its social media sites. And under pressure, it voluntarily removed its fruit and dessert flavors from retail stores.
- 78. The Individual Defendants breached their fiduciary duties by causing the Company to market its products through advertisements and representations that the use of the Company's ecigarettes and vaping devices was safer than traditional cigarettes, under circumstances where the Company lacked sufficient scientific proof and studies to substantiate the claims.

- 79. Even after public health officials issued public warnings about the safety of the Company's products, the Individual Defendants failed to take action to protect the Company from liability and adverse government action. In March 2018, Dr. Johnathan Winickoff, the former chair of the American Academy of Pediatrics Tobacco Consortium, stated that "JUUL is already a massive public-health disaster and without dramatic action it's going to get much, much worse." Dr. Winickoff, who is also a pediatrician at Massachusetts General Hospital and Professor at Harvard Medical School also noted that: "[i]f you were to design your ideal nicotine-delivery device to addict a large numbers of United States kids, you'd invent JUUL."
- 80. On April 10, 2019, the FDA Commissioner announced a possible link between seizures and e-cigarette use. The FDA's statement, entitled "Some E-cigarette Users Are Having Seizures, Most Reports Involving Youth and Young Adults," indicated that "The FDA has become aware that some people who use e-cigarettes have experienced seizures, with most reports involving youth or young adult users. The statement is available at https://www.fda.gov/tobacco-products/ctp-newsroom/some-e-cigarette-users-are-having-seizures-most-reports-involving-youth-and-young-adults, last visited Dec. 27, 2019.
- The Individual Defendants were also aware that Israel banned the import and sale of JUUL's e-cigarettes in August 2018, calling JUUL's high nicotine concentration levels "a danger to public health."
- 82. As a result of the Individual Defendants' wrongdoing, the Company and its shareholders have been harmed. On November 19, 2019, New York Attorney General Letitia James filed a lawsuit against JUUL Labs, accusing the company of using deceptive marketing practices that targeted minors and misleading consumers about the safety of its products.
 - 83. The FDA has issued a warning letter to the Company.
- As of December 17, 2019, the Center for Disease Control has indicated that 54 persons have died from vaping-related diseases. Deaths have been recorded in the District of Columbia and in 27 states.
- 85. In addition, the Company has been sued by numerous consumers who have been harmed due to use of the Company's products. One such case filed against the Company is *Castro v.*

1415

16

17

18 19

20

22

21

23 24

25

26

27 28 Juul Labs, Inc., Case No. 19-CIV-05786 (Superior Court for the State of California, County of San Mateo), filed Sept. 30, 2019. The plaintiff asserts various common law claims against the Company for failure to warn about the health risks of the Company's products. See also Smith v. Juul Labs, Inc., Case No. 3:19-cv-08375-WHO (N.D. Cal. Dec. 23, 2019) (same).

The Company has also been sued by several school districts (including Anaheim and 86. Compton school districts in California) which seek damages for the costs related to underage vaping. See, e.g., Mountain Grove School District v. Juul Labs, Inc., Case No. 3:19-cv-08402 (N.D. Cal. Dec. 24, 2019).3 The Mountain Grove School District complaint alleges that JUUL has unlawfully marketed its products to children, and that JUUL e-cigarettes' physical design is sleek, stylish, and easily concealed. In combination with JUUL's deceptive marketing, the complaint alleges that the ecigarette's design portrayed the device as a "must have" tech product, not a life-threatening nicotinedelivery device. The small USB-shaped design enables users to conceal the e-cigarette or, if not concealed, the device is often mistaken for a USB flash drive. The JUUL's battery indicator light also gratuitously flashes in "party mode" when the user shakes the device. According to plaintiff Mountain Grove School District, that feature is not necessary to the proper functioning of the device and intended solely to make the product appeal to youth. The complaint also alleges that contrary to JUUL's repeated representations that each JUUL pod contains nicotine "approximately equivalent to 1 pack of cigarettes or 200 puffs," JUUL's products actually deliver doses of nicotine that are materially higher than combustible cigarettes, with the goal of increasing nicotine addiction in consumers using the product.

87. The Mountain Grove School District complaint also alleges that by delivering such potent doses of nicotine, JUUL products magnify the health risks posed by nicotine, significantly increase blood pressure, and place users at a heightened (and concealed) risk for stroke, heart attacks and other cardiovascular events.

³ See also Fayette County Public Schools v. JUUL Labs, Inc. et al, Docket No. 3:19-cv-08368 (N.D. Cal. Dec 23, 2019).

sought to make JUUL's products successful by increasing the nicotine level of e-cigarettes, which

previously had not caught on with smokers due to lower nicotine delivery levels.

alternative to smoking traditional cigarettes, and thus the Company's employees were surprised by the major alliance with "Big Tobacco." As some JUUL employees have pointed out, the Altria deal could discredit the Company's proposition that it was striving to eliminate cigarettes by offering a safer alternative.

- 99. Defendant Burns, the Company's CEO at the time, frankly admitted that "We understand the controversy and skepticism that comes with an affiliation and partnership with the largest tobacco company in the U.S."
- loyalty by using the money disproportionately to pay themselves massive bonuses. They also failed to invest sufficient capital in the Company to strengthen JUUL's internal controls, R&D, and other projects, which, had they been made, would have protected the Company from the recent events that resulted in lawsuits, governmental investigations, and a \$19 billion decrease in the value of the Company.

SUBSTANTIVE UNFAIRNESS

- Defendants' conduct has been, and continues to be, substantively unfair to JUUL's minority shareholders.
- The prior transactions' between the Company and Defendants have also been substantively unfair. The Defendants obtained salaries, perquisites, bonuses and other payments that were obtained through mismanagement, self-dealing, and breaches of fiduciary duty. Moreover, the Individual Defendants breached their fiduciary duties of candor and good faith by failing to provide minority shareholders with all material information relevant to the value of JUUL stock, by failing to provide minority shareholders with similar liquidity for their stock comparable to that provided to Defendants, and by preferring their own interests over those of the Company. This conduct is continuing and threatens irreputable harm to Plaintiff and the Class. As a result, Plaintiff seeks a

⁶ See Kathleen Chaykowski, "New Altria Deal Makes Juul Cofounders Billionaires," FORBES, Dec. 20, 2018, available at https://www.forbes.com/sites/kathleenchaykowski/2018/12/20/new-altria-deal-makes-juul-cofounders-billionaires/#49f1f1f25a67.

⁷ *Id*.

28.

preliminary injunction enjoining JUUL and the Individual Defendants from engaging in any further self-dealing and an order requiring Defendants to disclose all material information about the Company and Defendants' transactions to Plaintiff and the Class.

PROCEDURAL UNFAIRNESS

- 103. Defendants' continuing course of conduct is also procedurally unfair to the Company's minority shareholders.
- Bowen and Monsees are using their control of the Company to cause the Board to rubber-stamp their self-dealing conduct. The Individual Defendants have all breached their duties of good faith, candor, and loyalty by failing to provide any information to minority shareholders, including failing to hold annual meetings of shareholders, failing to provide annual reports to minority shareholders, and failing to provide any other financial information about the Company to minority shareholders. Defendants, in stark contrast, have unfettered information about the Company and its financial condition.
- Defendants owe fiduciary duties of good faith, fair dealing, loyalty, candor, and due care to Plaintiff and the other members of the Class. As described herein, the Individual Defendants are breaching those fiduciary duties.
- Defendants have clear and material conflicts of interest and are acting to better their own interests at the expense of JUUL's minority shareholders. Defendants are engaging in self-dealing and not acting in good faith toward Plaintiff and the other members of the Class.

THE ENTIRE FAIRNESS STANDARD APPLIES TO DEFENDANTS' CONDUCT

- In transactions between controlling shareholders and the Company and/or its minority shareholders, the entire fairness standard applies. That standard applies here because Defendants paid themselves millions of dollars of bonuses after Altria's investment in the Company in 2018. Due to the payments, the transactions with Altria represented self-interested transactions from which Defendants have derived and continue to derive substantial personal benefits.
- 108. The entire fairness standard places the burden of proof on Defendants to affirmatively demonstrate the entire fairness both substantive fairness and procedural fairness of the challenged

transactions. It is not Plaintiff's burden to demonstrate the unfairness of such transactions, although such unfairness is evident from the detailed allegations set forth herein.

109. Because Defendants cannot demonstrate either substantive or procedural fairness to their self-interested transactions, such transactions must be set aside and/or they must be ordered to pay damages to Plaintiff and the Class.

DAMAGES TO JUUL

- harmed JUUL. Defendants used their control of JUUL to pay themselves huge bonuses when Altria made its investment in the Company in 2018, which cost the Company lost opportunities from investing the significant capital in higher and better uses which would have earned a return on investment. The Company has been damaged because using the capital infusion by Altria to expand the resources and capabilities of the Company would have helped to prevent the wrongdoing and mismanagement that has led to the governmental investigations and Congressional scrutiny, all of which has resulted in a multibillion dollar decline in the value of the Company's stock.
- The Defendants' mismanagement and wrongful conduct has also subjected the Company to lawsuits and governmental investigations. A former senior executive of the Company, Siddharth Breja, sued the Company in federal court in San Francisco, alleging that he was unlawfully retaliated against after he reported concerns about the health risks to consumers due to the Company shipping out vaping pods whose expiration dates had already occurred or were about to occur. He alleged that Defendants Burns and Danaher, the former CEO and CFO of the Company, respectively, had retaliated against him "with the full support of Juul's Board," and that Defendant Danaher had told him during work meetings that any concerns about expiration dates were unfounded since "Half our customers are drunk and vaping like mo-fo's, [so] who the f**k is going to notice the quality of our pods." *See Breja v. Jinul Labs, Inc.*, Case No. 3:19-cv-7148 (N.D. Cal.). As a result of the lawsuit, JUUL has been forced to spend, and will continue to expend, significant additional money in defense costs and litigation expenses.

In addition, as noted *supra*, JUUL is currently under investigation by the FDA and the United States Justice Department, as a result of which the Company has already expended significant attorneys' fees and costs.

A DEMAND ON JUUL'S BOARD WOULD BE FUTILE, AND THUS IS EXCUSED

- Plaintiff has not made a demand on the Board to institute this action against Defendants because, for the reason's detailed above and as further set forth below, any such demand would be a futile and useless act.
- Adam Bowen, James Monsees, K.C. Crosthwaite, Guy Cartwright, Jared Fix, and Gerald Masoudi as well as non-parties Joanna Engelke, Monika Fahlbusch, David Dickey, and Matt David.
- The facts detailed in this Complaint demonstrate that the JUUL Board is dominated and controlled by Defendants Bowen and Monsees. Demand is futile where controlling shareholders own voting stock of a company that allows them to control corporate actions, such as is the case with respect to Bowen and Monsees. Moreover, Bowen and Monsees' control is amply demonstrated by the facts alleged herein, including allowing themselves to sell at least \$500 million each of JUUL stock while denying similar opportunities for liquidity to the minority shareholders.
- Demand is excused as to Defendants Adam Bowen, James Monsees, K.C. Crosthwaite, Guy Cartwright, Jared Fix, and Gerald Masoudi because they are not independent and objective, and are completely dominated and controlled by Bowen and Monsees, who nominated them to the Board. Due to their voting control, Bowen and Monsees control all corporate action.
- Demand is also futile because a majority of the Board received improper personal financial benefits as part of the Altria investment. The directors are thus interested and are incapable of objectively considering a demand to bring suit. A pre-suit demand is therefore futile and excused.
- 118. Demand is also futile because the wrongful acts complained of in this Complaint evidence a pattern of conduct showing a wholesale abandonment of Defendants' fiduciary duties. These acts, and the other improper acts set forth in this Complaint, which demonstrate a pattern of misconduct, were not the product of a valid or good faith exercise of business judgment, nor could they have been.

FIRST CAUSE OF ACTION

Direct Class Claim for Breach of Fiduciary Duty Against the Individual Defendants and DOES 1-25

- Plaintiff repeats and realleges each allegation set forth herein.
- The Individual Defendants have violated their fiduciary duties of care, loyalty, candor, good faith, and independence owed to the minority shareholders of JUUL and have acted to put their personal interests ahead of the interests of JUUL's shareholders.
- By the acts, transactions, and courses of conduct alleged herein, the Individual Defendants, individually and acting as a part of a common plan, have violated their fiduciary duties to the minority shareholders of the Company.
- 122. As demonstrated by the allegations above, the Individual Defendants failed to exercise the care required, and breached their duties of loyalty, good faith, candor, and independence owed to the minority shareholders of JUUL because, among other reasons:
- (a) The Individual Defendants have failed to hold annual meetings and disseminate annual reports to Plaintiff and the Company's other minority shareholders, in violation of the law;
- (b) Monsees and Bowen are attempting to coerce and intimidate the Board they control into doing what they want without adequate investigation and analysis;
- (c) the Individual Defendants' conduct has decreased the value of the Company's stock by billions of dollars and the Individual Defendants are attempting to divest the minority shareholders of fair value for their JUUL stock without providing any information to the minority shareholders about the fair market value of their stock;
 - (d) the Individual Defendants are abdicating their fiduciary duties; and
- (e) the Individual Defendants are failing to ensure disclosure of all material facts to JUUL's minority shareholders regarding JUUL's financial results, prospects, and all material facts regarding the Company and the value of their stock in the Company.
- 123. The Individual Defendants further violated their fiduciary duties by failing to recuse themselves from consideration of self-interested transactions between the Company and Altria, with whom they have disabling conflicts, and by failing to ensure a fair and adequate procedural and substantive process for transactions between Altria and the Company.

£

- Because the Individual Defendants dominate and control the business and corporate affairs of JUUL, and are in possession of private corporate information concerning JUUL's assets, business, and future prospects, there exists an imbalance and disparity of knowledge and economic power between them and the minority shareholders of JUUL.
- By reason of the foregoing acts, practices, and course of conduct, the Individual Defendants have failed to exercise ordinary care and diligence in the exercise of their fiduciary obligations toward Plaintiff and the other members of the Class.
- As a result of the Individual Defendants' actions, Plaintiff and the Class have been and will be damaged in that they have not received similar liquidity opportunities for their stock as have the Individual Defendants and have been directly harmed with respect to the value of their shares of JUUL common stock.
- Unless enjoined by this Court, the Individual Defendants will continue to breach their fiduciary duties owed to Plaintiff and the other members of the Class, and will continue to withhold annual reports and financial information from minority shareholders and continue to engage in self dealing, which will exclude the Class from its fair proportionate share of JUUL's valuable assets and businesses, and/or benefit them in the unfair manner complained of herein, all to the irreparable harm of the Class.
- 128. The Individual Defendants are engaging in self-dealing, are not acting in good faith toward Plaintiff and the other members of the Class, and have breached and are breaching their fiduciary duties to the members of the Class.
- Plaintiff and the Class have no adequate remedy at law. Only through the exercise of this Court's equitable powers can Plaintiff and the Class be fully protected from the immediate and irreparable injury caused by Defendants' actions.

SECOND CAUSE OF ACTION

Direct Class Claim for Aiding and Abetting Breaches of Fiduciary Duties Against the Individual Defendants and DOES 1-25

130. Plaintiff incorporates by reference and realleges each and every allegation contained above, as though fully set forth herein.

- 131. In committing the wrongful acts alleged herein, Defendants have pursued, or joined in the pursuit of, a common course of conduct, and have acted in concert with and conspired with one another in furtherance of their common plan or design. In addition to the wrongful conduct herein alleged as giving rise to primary liability, Defendants further aided and abetted and/or assisted each other in breach of their respective duties as alleged herein.
- 132. The purpose and effect of Defendants' conspiracy, common enterprise, and/or common course of conduct is, among other things, to permit violations of law and breaches of fiduciary duties.
- Defendants have accomplished their conspiracy, common enterprise and/or common course of conduct by authorizing and/or ratifying the self-dealing conduct alleged herein, by wrongfully failing to hold annual meetings and disseminate annual reports, and by causing the Company to violate the law and failing to comply with applicable laws and regulations.
- Defendants each aided and abetted and rendered substantial assistance in the wrongs complained of herein. In taking such actions to substantially assist the commission of the wrongdoing described of herein, they acted with knowledge of the primary wrongdoing, substantially assisted the accomplishment of that wrongdoing, and were aware of their overall contribution to and furtherance of the wrongdoing. This wrongdoing facilitated Defendants' self-interested conduct and has harmed JUUL's minority shareholders.
- Plaintiff and the members of the Class will be irreparably injured as a direct and proximate result of the aforementioned acts, and have no adequate remedy at law.

THIRD CAUSE OF ACTION

Direct Class Claim For an Accounting, and for Declaratory and Injunctive Relief (Against the Individual Defendants and JUUL Labs, Inc.)

- 136. Plaintiff incorporates by reference and realleges each and every allegation contained above, as though fully set forth herein.
- 137. Defendants have breached their fiduciary duties of good faith, candor, and loyalty by failing to hold annual meetings of shareholders, failing to provide Plaintiff and the Company's other minority shareholders with annual reports and other financial information about the Company necessary

for Plaintiff and the Class to determine the financial condition of the Company and fair value of their shares, and other wrongful conduct, as alleged herein.

- 138. Plaintiff seeks injunctive relief in the form of an order of mandamus requiring the Individual Defendants and JUUL Labs, Inc. to comply with applicable law, including the provisions of the Corporations Code requiring the Company to hold annual shareholder meetings and issue annual reports to the shareholders, and other appropriate relief.
- Plaintiff also seeks a declaratory judgment that Defendants have breached their fiduciary duties to the Company and its minority shareholders.

FOURTH CAUSE OF ACTION

Direct Individual Cause of Action for Violation of California Corporations Code § 1601 et seq. Against Defendant JUUL Labs, Inc.

- 140. Plaintiff incorporates by reference and realleges each and every allegation contained above, as though fully set forth herein, except for the prior causes of action.
- 141. Plaintiff is a shareholder of record of JUUL and has been a Company shareholder at all relevant times.
- 142. By lawful means, Plaintiff requested to inspect the books and records of the corporation pursuant to Cal. Corp. Code'§ 1601, but the corporation has wrongfully refused the request. Plaintiff noted a proper purpose for his inspection demand to obtain information necessary to determine the value of his JUUL stock and to investigate breaches of fiduciary duty by Defendants and the Board. A true and correct copy of Plaintiff's inspection demand under Cal. Corp. Code § 1601 is attached hereto as **Exhibit A** and is incorporated herein by reference.
- 143. Plaintiff seeks an order of mandamus requiring the Company to comply with its obligations under Cal. Corp. Code § 1601 et seq.
- 144. Plaintiff also requests that, pursuant to Cal. Corp. Code § 1603, the Court "appoint one or more competent inspectors or accountants to audit the books and records kept in this state and investigate the property, funds and affairs of any domestic corporation or any foreign corporation keeping records in this state."
 - 145. Plaintiff has no adequate remedy at law.

FIFTH CAUSE OF ACTION

Derivative Claim for Breach of Fiduciary Duty Against the Individual Defendants and DOES 1-25

- Plaintiff repeats and realleges each allegation set forth herein, except for the causes of action.
- 147. The Individual Defendants owe fiduciary duties to the Company due to their positions as officers, directors, and controlling shareholders of JUUL Labs, Inc.
- The Individual Defendants have violated their fiduciary duties of care, loyalty, candor, good faith, and independence owed to JUUL and have acted to put their personal interests ahead of the interests of the Company.
- By the acts, transactions, and courses of conduct alleged herein, the Individual Defendants, individually and acting as a part of a common plan, have violated their fiduciary duties to the Company.
- As demonstrated by the allegations above, the Individual Defendants failed to exercise the care required, and breached their duties of loyalty, good faith, candor, and independence owed to JUUL because, among other reasons:
- (a) the Individual Defendants' conduct has caused significant harm to the Company and has decreased the value of the Company's stock by billions of dollars;
 - (b) the Individual Defendants have abdicated their fiduciary duties; and
- (c) the Individual Defendants have grossly mismanaged the Company and caused it to violate rules and regulations that are critical to the Company's operations and revenues.
- 151. The Individual Defendants further violated their fiduciary duties by failing to recuse themselves from consideration of self-interested transactions between the Company and Altria and misused the proceeds of the investment from Altria, siphoning off millions of dollars to themselves instead of investing the capital in uses that would have strengthened the Company and prevented it from violating the law and thus being exposed to the dozens of pending lawsuits against the Company.
- The Individual Defendants dominate and control the business and corporate affairs of JUUL, and are in possession of private corporate information concerning JUUL's assets, revenues, and projections. The Individual Defendants, while in possession of full information about the Company,

JURY TRIAL DEMAND

Plaintiff demands a trial by jury on all claims and issues so triable.

Dated: January 6, 2020

Respectfully submitted,

BOTTINI & BOTTINI, INC.

Francis A. Bottini, Jr. (175783)

Yury A/Kolesnikov (271173)

Francis A. Bottini, Jr.

7817 Ivanhoe Avenue, Suite 102

La Jolla, California 92037

Telephone: (858) 914-2001 Facsimile: (858) 914-2002

Counsel for Plaintiff Daniel Grove

24,

ClassAction.org

This complaint is part of ClassAction.org's searchable class action lawsuit database and can be found in this post: <u>Juul Labs Hit with Stockholder Derivative Suit in California</u>